Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


155P - Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients


24 May 2020




Emilia Montagna


Annals of Oncology (2020) 31 (suppl_2): S62-S82. 10.1016/annonc/annonc122


E. Montagna1, E. Pagan2, G. Cancello1, C. Sangalli1, V. Bagnardi2, E. Munzone1, M. Iorfida1, M. Mazza1, S. Dellapasqua1, N. Bianco1, P. Veronesi3, M.A. Colleoni1

Author affiliations

  • 1 Division Of Medical Senology, European Institute of Oncology IRCCS, 20141 - Milan/IT
  • 2 Department Of Statistics And Quantitative Methods, University of Milan-Bicocca, Milan/IT
  • 3 Division Of Senology, European Institute of Oncology IRCCS, 20141 - Milan/IT

Abstract 155P


Metronomic chemotherapy is a dosing schedule strategy that includes frequent, even daily, administration of chemotherapeutics at doses significantly below the maximum tolerated dose, without any planned prolonged drug-free breaks. Metronomic chemotherapy is an attractive treatment option for metastatic breast cancer (MBC) patients who required prolonged disease control without cumulative toxicity. Data available on the efficacy and tolerability of prolonged usage of metronomic therapy are limited.


We analyzed the patients with MBC who obtained prolonged clinical benefit for a duration of 12 or more months (complete remission, partial remission or stabilization of disease) with vinorelbine 40 or 30 mg orally 3 times a week, cyclophosphamide 50 mg daily, and capecitabine 500 mg 3 times a day (VEX regimen). The patients were treated in the outpatient department at the European Institute Oncology, Milan.


A total of 75 MBC patients were identified. The median age at the beginning of the VEX regimen was 54 years, 48% of patients had visceral involvement and 84% of patients had hormone-receptor positive and HER2 negative carcinoma. 39 patients received VEX as the first line treatment of MBC while 36 patients were pretreated, with 2 or more lines of treatment in 50% of cases. The objective response rate was 48% (95% CI, 36-60). The median duration of VEX after the first year was 13 months (range 0.3-81.3 months). The progression free survival at 3 years was 25.7% (95% CI, 16.4-36.1) and at 4 years was 19.0% (95% CI, 10.7-29.1; time 0 corresponds to 1 year after VEX start). 27 patients required a dose reduction, 1 case of febrile neutropenia was reported, no other G4 toxicity were registered. 7% of patients experienced G3 hand and foot syndrome.


Metronomic chemotherapy with VEX regimen can induce prolonged clinical benefit in MBC. Based on this long-term safety evaluation, there is no evidence of specific cumulative or delayed toxicities with metronomic chemotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


IEO Foundation.


E. Montagna, G. Cancello, E. Munzone: Advisory/Consultancy: Pierre Fabre. M.A. Colleoni: Advisory/Consultancy: Pierre Fabre, Pfizer, Obi Pharma, Puma Biotechnology Celldex AstraZeneca; Honoraria (self): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings